Drug firm Concordia overcharged NHS with 6,000% price rise, says watchdog

CMA accuses Canadian firm of overcharging by £100m on thyroid drug with price per pack rising from £4.46 to £258 in 10 years

Concordia International, the Canadian drug company, has overcharged the NHS by more than £100m in the past decade for a life-changing thyroid drug, according to Britain’s competition watchdog.

The Competition and Markets Authority (CMA) said it had provisionally found that Concordia had “abused its dominant position to overcharge the NHS” by hiking the price of liothyronine, used to treat patients with an underactive thyroid, by nearly 6,000% between 2007 and 2017.

Related: Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year

Continue reading…

Pharmaceutical Stocks


© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us